Cyclacel Pharmaceuticals ... (CYCC)
0.37
-0.02 (-4.64%)
At close: Jan 15, 2025, 11:47 AM
undefined% (undefined)
| Bid | 0.37 |
| Market Cap | 4.16M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -27.4 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.38 |
| Volume | 172,196 |
| Avg. Volume (20D) | 3,691,852 |
| Open | 0.37 |
| Previous Close | 0.39 |
| Day's Range | 0.36 - 0.38 |
| 52-Week Range | 0.31 - 4.00 |
| Beta | undefined |
About CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 16, 2004
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CYCC
Website https://www.cyclacel.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CYCC stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 2872.97% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Cyclacel Pharmaceuticals Inc. is scheduled to release its earnings on Mar 18, 2025,
during market hours.
Analysts project revenue of $10.00K, reflecting a -67.74% YoY shrinking and earnings per share of -0.29, making a -95.35% decrease YoY.
Analysts project revenue of $10.00K, reflecting a -67.74% YoY shrinking and earnings per share of -0.29, making a -95.35% decrease YoY.
1 week ago ·
Source
+24.02%
Cyclacel Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
2 months ago ·
Source
+9.76%
Cyclacel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.
